免疫系统
免疫疗法
癌症免疫疗法
T细胞
肿瘤微环境
癌症研究
嵌合抗原受体
细胞毒性T细胞
生物
抗原
化学
细胞生物学
细胞
树突状细胞
细胞毒性
细胞疗法
免疫原性
抗原提呈细胞
肿瘤抗原
串扰
免疫学
抗原呈递
获得性免疫系统
分泌物
作者
Lihua Yao,Yang He,Fangjian Shan,Xiaomeng Niu,Yichen Wang,Hengyuan Zhang,Sujian Wang,Gaojian Chen,Hong Chen
标识
DOI:10.1002/advs.202505387
摘要
Gene-engineered T cell therapies, particularly chimeric antigen receptor (CAR)-T cells, have demonstrated remarkable clinical success. However, concerns regarding insertional mutagenesis and other risks associated with genetic modification remain. Here, a non-genetic strategy is presented for T cell engineering using glycopolymer modification. It develops glycopolymer-modified T (G-T) cells based on antigen-specific T cells by integrating metabolic glycoengineering and click chemistry, yielding cells that retain T cell functionality while significantly enhancing tumor enrichment. The polyvalent glycopolymer-receptor interactions significantly improved the binding affinity of G-T cells to various glucose transporter 1 (GLUT1)-overexpressing tumor cells, resulting in increased cytotoxicity compared to unmodified T cells. In the tumor microenvironment, G-T cells engaged in stronger immune crosstalk with dendritic cells (DCs), upregulating interferon-gamma (IFN-γ) and interleukin-12 (IL-12) secretion and amplifying the anti-tumor immune response. Notably, despite the lower specificity of glycan-receptor interactions compared to antigen-antibody binding, the findings reveal an unexpected advantage: the "less restrictive" nature of glycan-receptor recognition enhances both tumor and immune cell interactions, triggering a potent immune cascade. This study establishes a universal, non-genetic T cell engineering strategy with broad applicability, offering a new perspective for tumor immunotherapy by merging biomedical polymer materials with immune modulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI